×
About 1,713 results

ALLMedicine™ Factor VII Center

Research & Reviews  612 results

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
https://clinicaltrials.gov/ct2/show/NCT04563520

Jan 13th, 2022 - The previous standard of care for high titer antibody eradication in hemophilia A (HA) included a labor-intensive, immune tolerance induction (ITI) regimen administered with concomitant bypassing agent (BPA) prophylaxis, either daily recombinant a...

Platelet Indices and Recurrent Pregnancy Loss
https://clinicaltrials.gov/ct2/show/NCT05190796

Jan 13th, 2022 - Recurrent pregnancy loss is defined as three or more consecutive pregnancy losses at or less than 20 weeks of gestation or with a fetal weight less than 500 gram. The American society for reproductive medicine (2008) proposed that recurrent pregna...

Cardiac inflammation and microvascular procoagulant changes are decreased in second wav...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641429
International Journal of Cardiology; Wu L, Baylan U et. al.

Dec 7th, 2021 - Compelling evidence has shown cardiac involvement in COVID-19 patients. However, the overall majority of these studies use data obtained during the first wave of the pandemic, while recently differences have been reported in disease course and mor...

A rapid, sensitive, and specific assay to measure TF activity based on chromogenic dete...
https://doi.org/10.1111/jth.15606
Journal of Thrombosis and Haemostasis : JTH; Østerud B, Latysheva N et. al.

Nov 26th, 2021 - Most tissue factor (TF) activity assays are based on measurement of factor X (FX) activation by TF in the presence of factor VII (FVII)/FVIIa. This requires long incubation, which may result in TF-independent activity of FX and inaccurate measurem...

Vaccination in children with inherited bleeding disorders: Does the use of plasma an d ...
https://doi.org/10.1111/hae.14461
Haemophilia : the Official Journal of the World Federatio... Tasar S, Tasar MA et. al.

Nov 21st, 2021 - We aimed to evaluate the vaccine seroconversion of paediatric patients with factor deficiency and to complete the missing vaccines. We also emphasize the importance of variables such as recombinant factor and plasma intake frequency. This prospect...

see more →

Guidelines  2 results

Damage control resuscitation in patients with severe traumatic hemorrhage: A practice m...
https://doi.org/10.1097/TA.0000000000001333
The Journal of Trauma and Acute Care Surgery; Cannon JW, Khan MA et. al.

Feb 23rd, 2017 - The resuscitation of severely injured bleeding patients has evolved into a multi-modal strategy termed damage control resuscitation (DCR). This guideline evaluates several aspects of DCR including the role of massive transfusion (MT) protocols, th...

Active management of the third stage of labour: prevention and treatment of postpartum ...
https://doi.org/10.1016/S1701-2163(16)34329-8
Journal of Obstetrics and Gynaecology Canada : JOGC = Jou... Leduc D, Senikas V et. al.

Nov 28th, 2009 - To review the clinical aspects of postpartum hemorrhage (PPH) and provide guidelines to assist clinicians in the prevention and management of PPH. These guidelines are an update from the previous Society of Obstetricians and Gynaecologists of Cana...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  26 results

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
https://clinicaltrials.gov/ct2/show/NCT04563520

Jan 13th, 2022 - The previous standard of care for high titer antibody eradication in hemophilia A (HA) included a labor-intensive, immune tolerance induction (ITI) regimen administered with concomitant bypassing agent (BPA) prophylaxis, either daily recombinant a...

Platelet Indices and Recurrent Pregnancy Loss
https://clinicaltrials.gov/ct2/show/NCT05190796

Jan 13th, 2022 - Recurrent pregnancy loss is defined as three or more consecutive pregnancy losses at or less than 20 weeks of gestation or with a fetal weight less than 500 gram. The American society for reproductive medicine (2008) proposed that recurrent pregna...

Influence of Cardiac Implantable Electronic Devices on the Hemostatic System
https://clinicaltrials.gov/ct2/show/NCT04499612

Sep 23rd, 2021 - 250 patients of similar age, gender, and ethnicity will be divided into five groups: Group A1-3: 150 patients with indications for cardiac implantable electronic device (CIED) implantation; Group B: 50 patients with an CIED implanted 8-10 years ag...

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors
https://clinicaltrials.gov/ct2/show/NCT02622321

Jun 24th, 2021 - This multicenter, open-label study will evaluate the safety, efficacy and pharmacokinetics of prophylactic emicizumab treatment in participants previously treated with episodic or prophylactic bypassing agents. Episodic bypassing agent participant...

Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven
https://clinicaltrials.gov/ct2/show/NCT03372993

Jan 8th, 2021 - This is a Non-interventional, observational, prospective evaluation of immunogenicity (neutralizing antibodies toward FVII) of patients with Hemophilia A or B with inhibitors, Factor VII Deficiency, Glanzmann's thrombasthenia, who have received on...

see more →

News  40 results

Venous Thromboembolism and Cancer: An Opportunity for Pharmacists to Optimize Care
https://www.onclive.com/view/venous-thromboembolism-and-cancer-an-opportunity-for-pharmacists-to-optimize-care

Dec 5th, 2020 - The management of venous thromboembolism (VTE) disorders is well described in the literature,1 and comprehensive guidelines are available from the American College of Chest Physicians.2 In addition, guidelines are available that specifically addre...

FDA approves recombinant treatment for hemophilia A or B with inhibitors
https://www.mdedge.com/hematology-oncology/article/220097/bleeding-disorders/fda-approves-recombinant-treatment-hemophilia
Christopher Palmer

Apr 2nd, 2020 - The Food and Drug Administration has approved a new rabbit-derived recombinant analog of human coagulation factor VII (Sevenfact) for the treatment of hemophilia A or B, according to a release from the agency. The treatment’s approval is for use i.

Bleeding disorders don’t carry increased risks for patients undergoing endoscopy
https://www.mdedge.com/hematology-oncology/article/196316/bleeding-disorders/bleeding-disorders-dont-carry-increased-risks
Andrew D. Bowser

Mar 13th, 2019 - When managed by an experienced team, patients with inherited bleeding disorders undergoing gastrointestinal endoscopy are not at increased bleeding risk, according to researchers reporting the largest series of such patients to date. The postendos.

Can Magnesium Stop Bleeding in ICH, Improve Outcomes?
https://www.medscape.com/viewarticle/884699

Aug 25th, 2017 - Lower levels of magnesium on hospital admission for intracerebral hemorrhage (ICH) are associated with larger hematoma volumes and growth, as well as worse functional outcomes at 3 months, suggesting an important role of magnesium in coagulation a...

Novel Hemophilia A Treatments Advance
https://www.medpagetoday.com/hematologyoncology/hemophilia/66523

Jul 10th, 2017 - The novel monoclonal antibody emicizumab substantially reduced bleeding risk in adolescents and adults with hemophilia A who have developed an immune response against standard factor VIII treatment, the phase III HAVEN trial showed. The drug, whic...

see more →